Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database

Sarmiento, Samuel; McColl, Michael; Musavi, Leila; Gani, Faiz; Canner, Joseph K.; Jacobs, Lisa K.; Fu, Fanmeng; Siotos, Charalampos; Habibi, Mehran

doi:10.1007/s10549-020-05556-y

Cited by 25 publications

(35 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data regarding the specific prognosis of MBC patients in the literature are conflicting, whereas more recent studies agree with a similar prognosis to that of FBC. 1,8,20 Based on a Chinese population with long-term follow-up, our study showed worse OS and DFS in MBC patients than in FBC patients. Multivariate analysis determined that in the whole population including MBC and FBC patients, endocrine therapy was an independent risk factor for OS and DFS.…”

Section: Discussionmentioning

confidence: 60%

“…Mainly in consonance with other studies, 7,20 our data suggest MBC patients tend to present with larger tumors and at a higher nodal stage, which may be related to lack of male mammogram screening and also less awareness of breast cancer. Additionally, MBC patients often present with a mass centrally located which has usually invaded the nipple as previously reported 1 …”

Section: Discussionmentioning

confidence: 62%

“…17 MBC patients contribute 1% to 1.2% of all breast cancers in Western countries. 1,7,8 According to the reports from Korea and Japan, the incidence of MBC is low (0.48 and 0.5%), 18,19 but the data from China remains limited. In our cohort, the incidence of MBC was 0.62%, which is similar to that in East Asian countries.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, MBC patients often present with a mass centrally located which has usually invaded the nipple as previously reported. 1 In Western countries, MBC has been reported to occur more often in older men with a median age at diagnosis in the mid-60s. In Korea, MBC was also diagnosed nearly 10 years later than FBC with a median age of 63-yearsold.…”

Section: Discussionmentioning

confidence: 99%

“…Compared to FBC patients, the incidence of breast cancer in men is lower, but its incidence has been shown to have increased by about 26% in the past two decades 17 . MBC patients contribute 1% to 1.2% of all breast cancers in Western countries 1,7,8 . According to the reports from Korea and Japan, the incidence of MBC is low (0.48 and 0.5%), 18,19 but the data from China remains limited.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Male breast cancer: A closer look at patient and tumor characteristics and factors associated with survival

et al. 2020

View full text Add to dashboard Cite

Background The prognostic effect of molecular subtypes on male breast cancer (MBC) remains unclear. The aim of this study was to evaluate the clinicopathological and prognostic factors of MBC patients. Methods From 1 January 1990 to 31 December 2014, the data of 152 MBC and 304 female breast cancer (FBC) patients were identified and extensively compared. Results Compared with the FBC group, MBC patients were found to have a higher rate of cancer family history (30.9% vs. 18.4%, P = 0.001), mass around the areola area (37.5% vs. 5.6%, P = 0.000), lymph node invasion (44.1% vs. 34.2%, P = 0.006) and hormonal receptor positivity (66.4% vs. 49.3%, P = 0.027). Luminal A was the most common subtype accounting for 69.8%, whereas HER2‐positive (12.7%) and TNBC (1.6%) subtypes were rare in the MBC group. However, it was significantly lower for MBC than for FBC who received endocrine therapy (38.8% vs . 49.3%, P = 0.041). MBC showed the worse overall survival (OS) and disease‐free survival (DFS) than those of FBC patients. However, 10‐year OS and DFS were similar between MBC and FBC patients in the subgroups of nonluminal subtype ( P < 0.001), but worse in MBC patients than those in FBC patients in the subgroups of luminal A ( P = 0.004 for OS; P = 0.002 for DFS) and luminal B ( P = 0.006 for OS; P = 0.003 for DFS). Multivariate analysis indicated tumor size, radical mastectomy and endocrine therapy as independent risk factors for OS and DFS of MBC patients. Conclusions Our study determined that MBC patients possessed a worse prognosis, usually with lymph node invasion, and were estrogen receptor (ER), progesterone receptor (PR)‐positive and human epidermal growth factor receptor (HER2)‐negative. Molecular subtypes based on FBC did not provide the same prognostic information in MBC, even in the luminal groups.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Male breast cancer: A closer look at patient and tumor characteristics and factors associated with survival

et al. 2020

View full text Add to dashboard Cite

show abstract

The association of race/ethnicity in male breast cancer survival within similar comorbidity cohorts

Parise

Caggiano

2023

Cancer

View full text Add to dashboard Cite

Background Concomitant disease is associated with poor breast cancer survival in women and is more prevalent in racial/ethnic minority groups than individuals who are non‐Hispanic White. The purpose of this study was to determine if race/ethnicity is associated with survival among men with breast cancer when stratifying analyses by level of comorbidity. Methods We used the California Cancer Registry to identify 1730 cases of men and 259,828 cases of women with breast cancer and documented Charlson Comorbidity Index (CCI). Kaplan–Meier survival and Cox regression analyses were used to compare breast cancer–specific survival and risk of mortality for African American/Black, Hispanic, and Asian/Pacific Islander men with White women and White men. Results When compared with White women, Black men with a CCI of 0 (hazard ratio [HR], 3.09; 95% CI, 1.10–1.16) and a CCI of 2+, (HR, 2.51; 95% CI, 1.42–4.42) had an increased risk of mortality when compared with White women. When compared with White men, African American men with a CCI of 0 (HR, 2.36; 95% CI, 1.45–3.85) and 2+ (HR, 2.44; 95% CI, 1.26–4.74) had an increased unadjusted risk of mortality, but these disparities were neutralized when controlling for sociodemographic and clinical factors. Conclusions Black men with both low and high levels of concomitant disease have an increased risk of mortality when compared with both White men and women, but demographic and clinical factors are contributors to this disparity.

show abstract

Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk

Strojnik

Krajc

Dragoš

et al. 2021

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose To analyze the prevalence of pathogenic/likely pathogenic variants (P/LPVs) in BRCA1 and BRCA2 genes in the largest cohort of Slovenian male breast cancer (MBC) patients to date and to explore a possible correlation between the Slovenian founder variant BRCA2:c.7806-2A > G and predisposition to MBC. Methods We performed a retrospective analysis of 81 MBC cases who underwent genetic counseling and/or testing between January 1999 and May 2020. To explore a possible genotype–phenotype correlation, we performed additional analyses of 203 unrelated families with P/LPVs in BRCA2 and 177 cases of female breast cancer (FBC) in carriers of P/LPVs in BRCA2. Results Detection rate of P/LPVs in the BRCA1 and BRCA2 genes was 24.7% (20/81) with 95% of them in BRCA2 gene. The only two recurrent P/LPVs were BRCA2:c.7806-2A > G and BRCA2:c.3975_3978dupTGCT (9 and 5 MBC cases, respectively). In families with BRCA2:c.7806-2A > G, the incidence of MBC cases was higher compared to families with other P/LPVs in BRCA2; however, the difference did not reach statistical significance (17.8% vs. 8.9%, p = 0.105). BRCA2:c.7806-2A > G was detected in both families with multiple cases of MBC. This splice-site variant represented a significantly higher proportion of all BRCA2 P/LPVs detected in MBC carriers compared to FBC carriers (47.4% vs. 26%, p = 0.049). Conclusion We observed a high mutation detection rate and conclude this may be due to the prevalent BRCA2:c.7806-2A > G variant in Slovenia. Our results indicate a possible association between this variant and higher risk of breast cancer in males compared to other identified P/LPVs in BRCA2.

show abstract

Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database

Cited by 25 publications

References 26 publications

Male breast cancer: A closer look at patient and tumor characteristics and factors associated with survival

Male breast cancer: A closer look at patient and tumor characteristics and factors associated with survival

The association of race/ethnicity in male breast cancer survival within similar comorbidity cohorts

Genetic testing results in Slovenian male breast cancer cohort indicate the BRCA2 7806-2A > G founder variant could be associated with higher male breast cancer risk

Contact Info

Product

Resources

About